Company Description

Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets.

It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.

Tharimmune, Inc. was founded in 2017 and is based in Red Bank, New Jersey.

Tharimmune, Inc.

Country	United States
Founded	2017
IPO Date	Jan 12, 2022
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Mark Wendland

Contact Details

Address: 34 Shrewsbury Avenue, Suite 1C Red Bank, New Jersey 07701 United States
Phone	732 889 3111
Website	tharimmune.com

Stock Details

Ticker Symbol	THAR
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.00
CIK Code	1861657
CUSIP Number	432705200
ISIN Number	US4327053090
Employer ID	84-2642541
SIC Code	2834

Key Executives

Name	Position
Mark Wendland	Chief Executive Officer and Director
Vincent LoPriore	Executive Chairman of the Board
Mark Toomey	President
Jacob Asbury	Chief Financial Officer
Dr. Nir Barak M.D.	Chief Medical Advisor

Latest SEC Filings

Date	Type	Title
Feb 3, 2026	SCHEDULE 13G	Filing
Feb 2, 2026	SCHEDULE 13G	Filing
Feb 2, 2026	8-K	Current Report
Jan 27, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 26, 2026	8-K	Current Report
Jan 22, 2026	8-K	Current Report
Jan 21, 2026	SCHEDULE 13G/A	Filing
Jan 20, 2026	8-K	Current Report
Jan 20, 2026	424B5	Filing
Jan 16, 2026	EFFECT	Notice of Effectiveness

View All SEC Filings